不同剂量阿托伐他汀联合依达拉奉对急性脑梗死患者血脂、炎症因子和脑血流指标的影响  

Effects of Different Doses of Atorvastatin Combined with Edaravone on Blood Lipid,Inflammatory Factors and Cerebral Blood Flow Indexes in Patients with Acute Cerebral Infarction

作　　者：刘悦[1] 王力[1] 王超[1] 刘晶晶[1] 刘广志 LIUYue;WANG Li;WANG Chao;LIU Jing-jing;LIU Guang-zhi(Department of Internal Medicine-Neurology,Beijing Anzhen Hospital Affiliated to Capital Medical University,Beijing,100029,China)

机构地区：[1]首都医科大学附属北京安贞医院神经内科,北京100029

出　　处：《现代生物医学进展》2021年第20期3871-3875,共5页Progress in Modern Biomedicine

基　　金：北京市科学技术委员会基金项目(z151100003915134)。

摘　　要：目的:探讨依达拉奉分别联合不同剂量的阿托伐他汀对急性脑梗死(ACI)患者血脂、炎症因子和脑血流指标的影响。方法:纳入2018年3月~2020年1月期间我院收治的81例ACI患者,采用随机数字表法分为低剂量组(依达拉奉联合10 mg/d阿托伐他汀治疗)、中剂量组(依达拉奉联合20 mg/d阿托伐他汀治疗)和高剂量组(依达拉奉联合40 mg/d阿托伐他汀治疗),每组各27例。对比三组疗效、血脂、炎症因子、脑血流指标、相关量表评分及不良反应。结果:治疗14 d后,高剂量组、中剂量组总有效率高于低剂量组,且高剂量组高于中剂量组(P<0.05)。治疗14 d后,高剂量组、中剂量组美国国立卫生研究院卒中量表(NIHSS)、改良Rankin量表(mRS)评分和总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、超敏C反应蛋白(hs-CRP)、白介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)低于低剂量组,且高剂量组低于中剂量组(P<0.05)。治疗14 d后,高剂量组、中剂量组高密度脂蛋白胆固醇(HDL-C)高于低剂量组,且高剂量组高于中剂量组(P<0.05)。治疗14 d后,三组平均血流速度较治疗前增加,外周阻力较治疗前降低(P<0.05),但三组间平均血流速度和外周阻力比较差异无统计学意义(P>0.05)。三组不良反应发生率组间对比差异无统计学意义(P>0.05)。结论:40 mg/d阿托伐他汀联合依达拉奉治疗ACI患者,可更加有效控制疾病进展,改善机体血脂、炎症因子,较为安全可靠,但有关脑血流的改变可能与阿托伐他汀剂量无关。Objective:To investigate the effect of edaravone combined with different doses of atorvastatin on blood lipid,inflammatory factors and cerebral blood flow in patients with acute cerebral infarction(ACI).Methods:A total of 81 patients with ACI in our hospital from March 2018 to January 2020 were selected,and they were randomly divided into low-dose group(edaravone combined with 10 mg/d atorvastatin),medium-dose group(edaravone combined with 20 mg/d atorvastatin)and high-dose group(edaravone combined with 40 mg/d atorvastatin),with 27 cases in each group.The curative effect,blood lipid,inflammatory factors,cerebral blood flow indexes,related scale score and adverse reactions of the three groups were compared.Results:14 d after treatment,the total effective rate of high-dose group and medium-dose group was higher than that of low-dose group,and the high-dose group was higher than that of medium dose group(P<0.05).14 d after treatment,the scores of National Institutes of Health Stroke Scale(NIHSS),modified Rankin Scale(mRS)scores and total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C),hypersensitive C-reactive protein(hs-CRP),interleukin-8(IL-8),tumor necrosis factor-α(TNF-α)of high-dose group and medium-dose group were lower than those of low-dose group,and the high-dose group was lower than the medium-dose group(P<0.05).14 d after treatment,the high-density lipoprotein cholesterol(HDL-C)of high-dose group and medium-dose group was higher than that of low-dose group,and high-dose group was higher than the medium-dose group(P<0.05).14 d after treatment,the mean blood flow velocity of the three groups was increased compared with that before treatment,peripheral resistance was lower than that before treatment(P<0.05),but there were no significant differences in the mean blood flow velocity and peripheral resistance among the three groups(P>0.05).There was no significant difference in the incidence of adverse reactions among the three groups(P>0.05).Conclusion:40 mg/d Atorvastatin combine

关 键 词：阿托伐他汀 依达拉奉 急性脑梗死 血脂 炎症因子 脑血流指标 

分 类 号：R743[医药卫生—神经病学与精神病学]